biotech fireworks | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical biotech fireworks

Previous 10 Next 10

To: tuck who wrote (2530)	6/15/2006 7:45:22 PM
From: zeta1961	of 7424

OMG..DSCO at a buck and change!..how are they keepin' the doors open? Haven't heard nothing about Surfaxin greasing up hinges-g- Elisabeth

Share	RecommendKeepReply Mark as Last Read

To: tuck who wrote (2530)	6/20/2006 11:20:22 AM
From: sjemmeri	of 7424

DSCO ~20 % on retaining advisory firm to evaluate options. Discovery Labs Retains Jefferies & Company to Assist in the Evaluation of Potential Strategic Alternatives June 20, 2006 07:00:26 (ET) WARRINGTON, Pa., Jun 20, 2006 (PRIMEZONE via COMTEX) -- Discovery Laboratories, Inc. (DSCO, Trade) today announced that it has engaged Jefferies & Company, Inc., the New York-based investment banking firm, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the future growth potential of the Company's surfactant replacement therapy pipeline and maximize shareholder value. Discovery is considering multiple alternatives including, but not limited to, potential business alliances, commercial and development partnerships, financings, business combinations and other similar opportunities. No assurances can be given that this evaluation will lead to any specific action or transaction. Discovery does not plan to make future comments about the status of the evaluation of strategic alternatives unless there are material developments. Discovery Laboratories, Inc. is a biotechnology company developing proprietary Surfactant Replacement Therapies (SRT) for multiple respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery's technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant. Discovery believes that its proprietary pulmonary surfactant platform has the potential to address multiple respiratory diseases where there are few or no approved therapies available. Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, commented, "The management and Board of Directors continuously evaluate our business to identify and develop opportunities for maximizing value for all shareholders. We look forward to working with Jefferies in this regard. While reviewing various strategic alternatives, the Company's immediate priorities are to address the manufacturing and regulatory requirements for FDA approval of Surfaxin(r), initiate Phase 2 clinical trials with Aerosurf(tm) and announce our next SRT programs to enter Phase 2 clinical development."

Share	RecommendKeepReply Mark as Last Read

From: nigel bates	6/21/2006 7:24:13 AM
	of 7424

Proteome up 18% in London on bid speculation.

Share	RecommendKeepReply Mark as Last Read

From: rkrw	6/23/2006 9:41:31 AM
	of 7424

PPCO +34% on oxymorphone approval. Market was unsettled heading in, worried about yet another approvable letter :-) So the stock is back to where it was a month or two ago.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: rkrw who wrote (2534)	6/27/2006 2:26:42 PM
From: tuck	of 7424

DSCO on apparent progress with their manufacturing issues, 16%. CYTR on no news, but perhaps anticipation of HIV trial results due shortly, 18%. Cheers, Tuck, who not so cheerfully, owns neither (but did own DSCO before it crashed again). Still thinking DSCO might recover and get Surfaxin approved next year.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: tuck who wrote (2535)	6/29/2006 7:00:52 PM
From: Mike McFarland	of 7424

Ah Arqule! Up 18% today and ran up to $5 from very close to $4 yesterday. Oh what a nice trade that would have been, and 2 million shares shorts being squeezed.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Mike McFarland who wrote (2536)	6/29/2006 9:04:10 PM
From: tom pope	of 7424

Stupid me, I was waiting for tomorrow. zero position :-(

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

From: tnsaf	6/29/2006 9:16:02 PM
	of 7424

BTRX +19% on slightly higher than average volume. Quite a few stocks had strong finishes.

Share	RecommendKeepReply Mark as Last Read

To: tom pope who wrote (2537)	6/30/2006 10:45:26 AM
From: Mike McFarland	of 7424

I've been watching it, but never intended to trade it. One of the yahooligans, a few days ago, suggested arqule might trade the lowest on friday with large volume to cover the short position, associated with Russell rebalancing. Sounded plausible, it may yet drop down again and allow the shorts to cover a notch cheaper. I trust Wall Street as far as I can spit, everything looks like a trap to me. Even this apparently cheap stock could be a trap. But I am pretty sure that I am not paranoid <g>

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Mike McFarland who wrote (2539)	6/30/2006 12:54:15 PM
From: Ian@SI	of 7424

Mike, of course you're not paranoid. EVERYONE really is out to get you. <G>

Share	RecommendKeepReply Mark as Last Read Read Replies (1)